New evidence-based information tools from AHRQ are available to help clinicians, policymakers, parents and caregivers make informed treatment decisions about infantile hemangioma (IH), a birthmark caused by abnormal growth of blood vessels. IH is more commonly found in white babies, girls and babies born before 37 weeks of pregnancy. Aresearch summary and a freecontinuing education moduleare available for clinicians who treat children with IH. Abrochure for parents and caregivers of children with IH supports discussions about the benefits and harms of various treatment options, including the use of prescription drugs (such as beta blockers and steroids) and surgery. A research summary for policymakers features considerations for possible health care programs and policy initiatives. The new tools from AHRQ’sEffective Health Care Program are based on a systematic review that evaluated the effectiveness, comparative effectiveness and harms of treatment options for patients with infantile hemangioma.